Yong Ping Zhang

US Patent:

7629372, Dec 8, 2009

Filed:

Sep 12, 2005

Appl. No.:

11/662808

Inventors:

James F. Dropinski - Colts Neck NJ, US
Guo Q. Shi - Monmouth Junction NJ, US
Yong Zhang - West Windsor NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/423
C07D 261/20

US Classification:

514379, 548240, 548241, 514378

Abstract:

A class of compounds having Formula I and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of developing conditions and sequelae that are associated with these diseases, such as atherosclerosis.

US Patent:

7807692, Oct 5, 2010

Filed:

Jun 30, 2006

Appl. No.:

11/922628

Inventors:

James F. Dropinski - Colts Neck NJ, US
Peter T. Meinke - Scotch Plains NJ, US
Guo Q. Shi - Monmouth Junction NJ, US
Yong Zhang - West Windsor NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/47
A61K 31/42
A61K 31/44
C07D 413/00
C07D 215/02
C07D 263/00

US Classification:

514307, 514314, 514376, 514340, 5462714, 546166, 548227

Abstract:

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

US Patent:

7834036, Nov 16, 2010

Filed:

Mar 3, 2006

Appl. No.:

11/884802

Inventors:

Harold B. Wood - Westfield NJ, US
Peter T. Meinke - Scotch Plains NJ, US
Guo Q. Shi - Monmouth Junction NJ, US
Yong Zhang - West Windsor NJ, US

Assignee:

Merck Sharp & Dohme Corp - Rahway NJ

International Classification:

A61K 31/443
C07D 413/04

US Classification:

514338, 5462721

Abstract:

Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidermia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

US Patent:

8552022, Oct 8, 2013

Filed:

Aug 3, 2010

Appl. No.:

13/390147

Inventors:

Harold B. Wood - Westfield NJ, US
Alan D. Adams - Holland NY, US
Jason W. Szewczyk - New York NY, US
Yong Zhang - West Windsor NJ, US
Meng Yang - Westfield NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/505
C07D 239/02
C07D 403/04

US Classification:

514275, 544330, 544295, 544331

Abstract:

Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

US Patent:

20060165821, Jul 27, 2006

Filed:

Dec 26, 2003

Appl. No.:

10/540817

Inventors:

Yong Zhang - Jamaica NY, US
Fei Ye - Beijing, CN
Fan Li - Beijing, CN

International Classification:

A61K 36/539
A61K 31/737
A61K 31/7008

US Classification:

424741000, 514062000, 514054000

Abstract:

This invention described various formula composite of for various diseases and conditions. The formula takes the advantage of our recent discovery of can inhibit cyclooxygenase-2 (COX-2) activity and expression, resulting in decrease of prostaglandin synthesis. COX-2 is involved in many biological processes, such as inflammation, pain, carcinogenesis, etc. Combination of with lycopene can be used for cancer prevention, especially smoking induced. Combination of with glucosamine and chondroitin can be used for arthritis. Finally, this invention disclosed various method to prepare this formula and composition.

US Patent:

20130071374, Mar 21, 2013

Filed:

Apr 17, 2012

Appl. No.:

13/449095

Inventors:

Masayori Inouye - New Brunswick NJ, US
Junjie Zhang - Edison NJ, US
Yong Long Zhang - Highland Park NJ, US

Assignee:

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Somerset NJ

International Classification:

C12N 9/22
C12P 19/34
A61K 38/46
C12Q 1/44

US Classification:

424 9461, 435 61, 435199, 435 912, 536 232

Abstract:

The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

US Patent:

20130217660, Aug 22, 2013

Filed:

May 12, 2011

Appl. No.:

13/642584

Inventors:

John S. Debenham - Scotch Plains NJ, US
Thomas H. Graham - Scotch Plains NJ, US
Matthew J. Clements - Old Bridge NJ, US
Yong Zhang - West Windsor NJ, US

International Classification:

C07C 237/24
C07D 295/155
A61K 31/165
C07D 213/40
A61K 31/5377
C07D 241/12
C07D 239/26
A61K 31/397
C07D 205/04
A61K 31/4453
A61K 31/40
C07D 233/61
A61K 31/4164
A61K 45/06
C07C 271/24
C07D 213/61
A61K 31/5375

US Classification:

51421002, 5142395, 544169, 564167, 514619, 544131, 5142355, 544120, 5142358, 544122, 564157, 514616, 564155, 51421001, 548950, 514331, 546234, 548567, 514428, 5483381, 514399, 514346, 514249, 514485, 514479, 560 27, 544163, 564168, 514460

Abstract:

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

US Patent:

20210324056, Oct 21, 2021

Filed:

Jul 23, 2019

Appl. No.:

17/250448

Inventors:

- Tokyo, JP
Chad J. SWANSON - Woodcliff Lake NJ, US
Yong ZHANG - Woodcliff Lake NJ, US
Shobha DHADDA - Woodcliff Lake NJ, US
Jinping WANG - Woodcliff Lake NJ, US
Lynn KRAMER - Woodcliff Lake NJ, US

International Classification:

C07K 16/18
A61K 31/542
A61P 25/28

Abstract:

Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.